Clinical Trial: Protecting Against Lenacapavir Misinformation With Young Women in Gauteng, South Africa ( PROTECT-L)

U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07518914) titled 'Protecting Against Lenacapavir Misinformation With Young Women in Gauteng, South Africa ( PROTECT-L)' on April 01.

Brief Summary: Adolescent girls and young women (AGYW) in South Africa remain disproportionately affected by HIV, with prevalence among 15-24-year-olds at 9.4% in 2024 despite expanded access to condoms, HIV testing, and oral PrEP. While oral PrEP is effective, its reliance on daily adherence and regular follow-up has limited impact for many young women. Lenacapavir (LEN), the first long-acting injectable PrEP administered twice yearly, offers a promising alternative that could improve persistence and protection. Howev...